.1]nonane (bispidine) based nicotinic acetylcholine receptor (nAChR) ligands have been synthesized and evaluated for nAChRs interaction. Diverse spacer motifs were incorporated between the hydrogen bond acceptor (HBA) part and a variety of substituted (hetero)aryl moieties. Bispidine carboxamides bearing spacer motifs often showed high affinity in the low nanomolar range and selectivity for the α4β2* nAChR. Compounds 15, 25, and 47 with K i values of about 1 nM displayed the highest affinities for α4β2* nAChR. All evaluated compounds are partial agonists or antagonists at α4β2*, with reduced or no effects on α3β4* with the exception of compound 15 (agonist), and reduced or no effect at α7 and muscle subtypes.
Introduction
(Di)azabicyclic templates dominate compound libraries for nicotinic acetylcholine receptors (nAChRs). 1 NAChRs are pentameric cation channels found in the central and peripheral nervous systems, as well as in non-neuronal cells and serve as interesting targets especially for various brain diseases. [2] [3] [4] [5] These (di)azabicyclic templates display cationic/HB cores important for the interaction with the receptors. An additional pharmacophoric point, a hydrogen bond acceptor (HBA) motif, is often introduced as a pyridine moiety and less often as carbonyl functionality or as heteroaryls. 6, 7 The bulkiness of ring structures containing the potentially charged nitrogen and moieties attached to the HBA system influence both affinity and functionality. 8 The diazabicyclic scaffold 3,7-diazabicyclo[3.3 .1]nonane (bispidine) originated from the natural product and nAChR ligand cytisine 1 (Fig. 1 ). It is a privileged scaffold and has been used for the development of nAChR compounds. 6, 7, [8] [9] [10] [11] [12] [13] [14] [15] In our previous 3,7-diazabicyclo[3.3. 1]nonane project, we explored the influence of different non-heteroaryl based HBA systems. 7 We also reported that 3,7-diazabicyclo[3.3.1] nonane is active on nAChRs and that some 3,7-diazabicyclo[3.3 .1]nonane carboxamides showed selectivity for the α4β2* nAChR. Herein, we extend the previous study by introducing spacer motifs like methylene, ethylene, ethenylene, ethynylene or (hetero)aryls attached to the HBA system to explore the chemical space for nAChRs further (Fig. 1) . Diverse substituents were connected to the spacer motifs.
Firstly, we synthesized and tested four cytisine derivatives including the in vivo active 3-(pyridine-3-yl)-cytisine (3PC) 5 displaying at least one rotatable bond and compared them with their analogously substituted 3,7-diazabicyclo[3.3 .1]nonane carboxamides to get insight into the influence of a spacer motif. [16] [17] [18] We have recently shown that 3-(pyridine-3-yl)-cytisine (3PC) 5 serves as an interesting lead for the development of antidepressants. [16] [17] [18] Now, we want to "open" the "chemical space" of cytisine to have the possibility to obtain compounds with better subtype selectivity pattern than cytisine derivatives along with a much simpler synthetic approach. Secondly, we prepared and tested a series of carboxamides bearing different spacer motifs providing additional possible interaction points with nAChRs and their consequences on affinity and functionality for further profiling projects.
Results and discussion

Chemistry
Like previously described by us, (-)-cytisine was isolated from seeds and pods of Laburnum anagyroides. 16, 17 The dried and milled plant material was extracted with PE to remove lipids. Then (-)-cytisine was extracted with a mixture of CH 2 Cl 2 :MeOH:NH 3 (90:10:5) for 8 hours. After filtration and concentration of this solution, it was extracted with HCl (1N) and, subsequently, rendered alkaline, and extracted with CH 2 Cl 2 until completion. The alkaloid 1 was finally purified by column chromatography on silica gel with a mixture of CHCl 3 and MeOH (6:1) or by preparative HPLC using a C 18 -RP stationary phase and a MeOH-H 2 O gradient.
The N-tboc protection group was introduced by adding di-tert-butyl dicarbonate ((Boc) 2 O) to a solution of (-)-cytisine 1 and Na 2 CO 3 in a mixture of CH 2 Cl 2 and H 2 O. The solution was heated to reflux for 2 h and N-tboc-cytisine 2 was obtained in good yields after extraction and recrystallization in PE. Alternatively, N-tboc-cytisine 2 was synthesized by adding portions of (Boc) 2 O to a solution of 1 and Na 2 CO 3 in a mixture of CH 2 Cl 2 and H 2 O until the (-)-cytisine spot 1 has disappeared on TLC. After extracting the product 2 it was purified by preparative HPLC using a C 18 -RP column and a MeOH-H 2 O gradient.
The reaction of N-tboc-cytisine 2 with N-bromosuccinimide (NBS) for 2 h under reflux in CH 2 Cl 2 afforded a mixture of isomeric bromo-N-tboc-cytisine derivatives bearing the bromo substituents in the 3 or the 5 position of the pyridone moiety. These isomers could be separated by preparative HPLC using a C 18 -RP column and a MeOH-H 2 O gradient. Only 3-bromo-N-tboc-cytisine 3 was used for this project.
The cytisine derivatives 4 -7 were synthesized in a two-step process incorporating a crosscoupling reaction and the N-tboc-deprotection step. The coupling of aromatic or heteroaromatic moieties to the cytisine backbone was achieved by using the Suzuki-Miyaura reaction in a microwave synthesizer. The palladium catalyst Pd(PPh 3 ) 4 was added to a solution of 3-bromo-N-tboc-cytisine 3, the appropriate boronic acid and an inorganic base in a mixture of DME or DMF and H 2 O. Microwave irradiation (30 W) at 80 °C was used for 30 to 90 minutes to synthesize the according N-tboc protected cytisine derivatives Boc-4 -Boc-7. These products were purified on preparative HPLC using a C 18 -RP column and a MeOH-H 2 O gradient.
The N-tboc protection group of Boc-4 -Boc-7 was directly removed by using microwave irradiation (150 W) at 150 °C for 30 minutes in pure H 2 O. The solvent of the final cytisine products 4 -7 was removed by lyophilisation for at least 24 h. The 3, .1]nonane (bispidine) scaffold was synthesized using the method described previously, where N-benzyl-N′-tboc-bispidinone 9 was obtained by a double Mannich reaction from commercially available tert-butyl 4-oxopiperidine carboxylate 8, benzylamine, and paraformaldehyde and reduced to the key intermediate N-benzyl-N′-tbocbispidine 10. 7, 13 The cleavage of the N-benzyl protecting group from N-benzyl-N′-tbocbispidine 10 was achieved by using palladium on activated charcoal (Pd/C) 5 % under a hydrogen atmosphere. The resulting N-tboc-bispidine 12 was now used as the starting material for all carboxamides described.
In general, all N-tboc protected intermediates Boc-13 -Boc-55 were purified by flash chromatography on silica gel and analyzed by LC-MS. When the purity was above 90-95 % these intermediates were N-tboc deprotected without further analysis. The N-tboc deprotected final compounds 13 -55 were purified by flash chromatography and have been analyzed in more details.
(K i = 39.6 nM) for the α4β2* subtype compared to compound 16. So, small electron withdrawing groups in the meta or para position increase the affinity for the α4β2* subtype and it seems that the position of the small electron withdrawing or donating substituent might be more important than its electronic properties.
The affinity for the α4β2* nAChR subtype was decreased when the phenyl ring of compound 16 was replaced by smaller five-membered, aromatic rings systems, such as furanyl (compound 22) or thiophenyl (compounds 23 and 24). K i values were 287.5 nM for the 2-furanyl (22) , 96.9 nM for the 2-thiophenyl (23) , and 57.1 nM for the 3-thiophenyl derivative (24) . When the phenyl ring of compound 16 was replaced by a 3-pyridyl (41) or a 4-pyridyl moiety (25) , the affinity increased for the α4β2* subtype (41: K i = 32.6 nM; 25: 1.03 nM). The K i values of the 3-pyridyl compound 41 and its less rigid counterpart (compound 39, K i = 39 nM) are very similar for α4β2*, indicating that both spacer motifs allow similar orientation in the binding pocket. When the simple phenyl moiety of compound 16 was extended by a fused 3,4-methylendioxy moiety (compound 26), a K i value of 36.9 nM was obtained for the α4β2* nAChR subtype. The extension to a 1-naphthyl ring system (compound 27), however, decreased the affinity for the α4β2* subtype (K i = 296.6 nM).
3,7-Diazabicyclo[3.3.1]nonane based carboxamides with an ethynylene spacer -Compound 42 displayed a 5-times higher affinity for the α4β2* nAChR subtype (K i = 10.9 nM) than its more flexible analogs 32 and 16. The introduction of an electron donating methoxy group (compound 43) caused a drop in affinity for α4β2* (K i = 241.9 nM). A similar observation was made for compound 17, which means that ortho substitutions are less tolerated by the receptor. Small electron donating or withdrawing groups at meta and/or para positions (compounds 44-50) increased the affinity for the α4β2* subtype (up to about 11 fold). E.g. a methoxy group in the meta or para position increased the affinity slightly (44: K i = 6.3 nM; 45: K i = 7.8 nM) and a di-substitution (compound 46) resulted in an even higher affinity for the α4β2* subtype (K i = 2.1 nM). The combination of a 3-chloro/4-methoxy substitution (compound 47) resulted in a compound with the highest affinity in this compound library (K i = 0.991 nM). Compound 48, bearing a 4-methyl group displayed the same affinity (K i = 10.9 nM) for the α4β2* nAChR subtype as the unsubstituted compound 42. 3-Fluoro substitution (compound 49) also provided a ligand with high affinity for α4β2* (K i value of 7.1 nM). The affinity of compound 50 (3,4-methylendioxy substituent; K i = 3.13 nM) is similar to its ring open 3,4-dimethoxy analog 46 (K i = 2.1 nM), and both compounds possess about a 10-fold higher affinity than its analog bearing a vinyl spacer (26) . A 1-naphthyl moiety (compound 51) decreased affinity for the α4β2* subtype (K i = 46 nM) compared to compound 42. A similar observation has been made with compounds 27 vs. 16. In summary, bispidine compounds bearing an ethynylene spacer moiety along with substitutions in the meta-and/or para position are well tolerated by the α4β2* nAChR subtype.
3,7-Diazabicyclo[3.3.1]nonane based carboxamides with an (hetero)aryl spacer-As previously reported, the biphenyl derivative 28 has a K i value of 39.9 nM for α4β2* nAChR, and about 1,100 nM for the α3β4* subtype. 7 In line with the observations for compounds 31 and 36 vs. 30, 39 vs. 32, and 41 and 25 vs. 16, the replacement of the phenyl moiety by 3-or 4-pyridyls increased the affinity for the α4β2* nAChR subtype (3-pyridylphenyl derivative 52: K i = 25 nM; 4-pyridyl-phenyl derivative 53: K i = 7.1 nM). Additionally, the replacement of the phenyl ring by an imidazolyl ring (compound 54) also increased affinity for the α4β2* subtype (K i = 5.6 nM). The phenyl group is tolerated as a spacer motif for α4β2* nAChRs. Compound 55, where a 4-pyridyl substituent was connected via a thiazole spacer with the bispidine amide backbone, did not show any affinity for nAChRs. Similar observations have been made on the previous set of bispidine compounds, when heteroatoms in close proximity to the HBA system caused a dramatic drop in affinity. 7 In summary, various spacer moieties like methylene, ethylene, ethenylene, ethynylene or phenyl, between the HBA motif and (hetero)aryl moieties are tolerated by the α4β2* nAChR subtype, even with high affinity and subtype selectivity.
Most compounds showed partial agonism/antagonism in initial characterization assays using previously described electrophysiological experiments with diverse nAChRs expressed in Xenopus oocytes ( Figure 2 ). 7, [23] [24] [25] Compounds 35, 15, 46, 47, 50, 52, 53, and 54 produced the strongest antagonistic effects for α4β2* receptors. Compound 35 was further evaluated and recently discovered as an in vivo active, highly selective agent with antidepressive effect in a mouse model. 26 Compound 15 was the most potent agonist at α3β4* in this compound series. No strong effects were observed for α7 subtype. Compound 46 had some antagonistic effect at the muscle subtype. In general, spacer motifs lead to compounds with partial agonist/antagonist profiles with the strongest effects observed for α4β2* nAChRs. In contrast, the cyclopropyl spacer (trans form) produced compound 15 with an additional α3β4* agonistic profile.
Physicochemical properties and drug-likeness
Physicochemical properties and druglikeness parameters ClogP, TPSA, and logBB were calculated using ACD/ADME Suite 5.0 (ACD/Labs) software. Most compounds are in the range for CNS druglikeness parameter values (M r : 250 and 350; ClogP: between 1-3; PSA < 75). Additional parameters important for CNS compounds have been calculated (Table 3; supplementary data) for those compounds showing nanomolar affinity for α4β2* (K i < 1,000 nM). 27 Most active compounds showed "good" values (see Table 3 ; supplementary data). There were no correlations between affinity and ClogP or TPSA values or rotatable bonds. Most compounds have 2-3 rotatable bonds due to their spacer motif which had an influence on their functionality like stated above. For the likelihood of blood brain barrier (BBB) penetration, logBB values were calculated can be from logP and TPSA values where logBB values below −0.5 would reflect very poor or no BBB penetration and > 0.7 very high penetrants. 3,7-diazabicyclo[3.3.1] nonane carboxamides bearing the ethenylene or ethynylene spacer could function as Michael acceptors, properties which should be avoided for potential drug candidates for chronic treatment. Results derived from these compounds serve as a basis for further compound profiling projects and therefore an important part in this early SAR study.
Conclusions
In summary, we synthesized and evaluated a small set of cytisine (4) (5) (6) (7) derivatives and a series of 3,7-diazabicyclo[3.3 .1]nonane carboxamide for their affinities at various nAChRs. Selected compounds were screened for agonist and antagonist functionality. Most compounds displayed α4β2* subtype selectivity regarding their affinities measured.
Cytisine derivatives 4-7 were compared with the four analogously substituted bispidine derivatives 30, 31, 36, and 37. Their affinities for the α4β2* nAChR were in the same range. It seems that the impact of flexibility/rigidity on α4β2* affinity is of minor importance. The introduction of an additional hydrogen bond acceptor (HBA) motif, e.g. pyridyl groups, increased the affinity for the α4β2* subtype in both sets of derivatives.
The incorporation of spacer moieties like methylene, ethylene, ethenylene, ethynylene or phenyl at the 3,7-diazabicyclo[3.3.1] nonane carboxamide template increased the affinity for the α4β2* nAChR. Heteroaryl substituents with HBA functionality increased the affinity for α4β2* nAChR further.
Compounds 15, 25, and 47 with K i values of about 1 nM showed the highest affinities for α4β2* nAChR.
From the electrophysiology point of view, all evaluated compounds displayed partial agonism or antagonism at α4β2*, reduced or no effects on α3β4* with the exception of compound 15 (agonist), and reduced or nor effect at α7 and muscle type.
Experimental section
All reagents and solvents were obtained from various suppliers (ABCR, Acros, Aldrich, Alfa Aesar, Fluka, Merck or Sigma) and used without further purification unless otherwise noted. Dichloromethane was freshly distilled from calcium hydride. Methanol was treated with sodium, distilled afterwards and stored under nitrogen. Sodium wires were used to dry diethyl ether, petroleum ether, tetrahydrofuran, and toluene. Water was taken from a water purification system PureLab Plus UV (ELGA Labwater) or Direct-Q™ 5 (Millipore). Amines were purified prior to use with a Kugelrohr distillation apparatus (Büchi). Reactions were monitored by thin-layer chromatography (TLC) using aluminum sheets coated with silica gel 60 F 254 (Merck). Compounds were visualized using UV light (254 or 365 nm) and using a KMnO 4 (1 %). Column chromatography was carried out on silica gel (0.035-0.060 nm) using different mixtures of CH 2 Cl 2 with MeOH (40:1, 20:1 or 9:1) or of PE with EtOAc (4:1 or 3:1) as mobile phases. 1 H NMR spectra (400 or 500 MHz) and 13 C NMR spectra (100 or 125 MHz) were recorded on an Avance 400 or on an Avance 500 NMR spectrometer (Bruker). All NMR spectra were recorded at rt. Chemical shifts (δ) are given in parts per million (ppm) relative to the remaining protons of the deuterated solvents used as internal standard. Coupling constants J are given in Hertz (Hz) and spin multiplicities are given as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet) and br (broad). Mass spectra were recorded on an API 2000 mass spectrometer with an electron spray ionization source (Applied Biosystems) coupled to an Agilent 1100 HPLC system (LC/ESI-MS) or on a Varian 500-MS mass spectrometer (ESI-MS). The purity of the compounds was determined by LC/ESI-MS or a Shimadzu Prominence HPLC system at an appropriate wavelength. HRMS runs were performed on Agilent Technologies 6530 Accurate-Mass Q-TOF LC/MS. All compounds proved to possess ≥95 % purity. Melting points were determined in open capillary tubes with a melting point apparatus (WeissGallenkamp) or with a Melting Point B-540 (Büchi) and are uncorrected. Infrared spectroscopy was performed with a Tensor-27 FTIR infrared spectrometer (Bruker Optic) using KBr pellet or with a Nicolet iS10 (Thermo Scientific). Elemental microanalyses (C, H, N) were performed with a VarioEL apparatus (Elementar Analysensysteme) or a Costech elemental combustion apparatus and the determined values are generally within ±0.4 % of the theoretical values. Hydrogen for hydrogenations was produced by a Hogen GC hydrogen generator (Proton Energy Systems) or by a 60H hydrogen generator (Parker, domnick hunter). Lyophilizations were performed with an Alpha 1-4 LSC freeze dryer (Martin Christ).
General procedure A: Suzuki cross-coupling reaction with 3-bromo-N-tboc-cytisine
3-Bromo-N-tboc-cytisine (100 mg, 0.27 mmol), the appropriate boronic acid (0.41 mmol), a base (0.6 mmol), DME (3 mL) and H 2 O (1 mL) were added into a 10 mL microwave glass tube. The solution was washed with argon for 10 min. After the addition of Pd(PPh 3 ) 4 (30 mg, 0.027 mmol) the reaction vessel was sealed with a septum and placed into the microwave cavity. Microwave irradiation of 30 W was used and the temperature ramped from rt to 80 °C. Once 80 °C was reached the reaction mixture was held for 30 to 90 min. before the mixture was allowed to cool to rt. The reaction vessel was opened and the solvents were evaporated under reduced pressure. The brown residue was extracted on a C-18 SPE column eluting with a mixture of MeOH/H 2 O 70:30 or 60:40 v/v and the aqueous solution was concentrated under reduced pressure, subsequently. The residue was purified on a preparative HPLC system using RP C-18 silica gel and appropriate MeOH/H 2 O gradients. The chromatograms were scanned at 254 nm and the appropriate fractions were collected. The fractions containing the desired products were concentrated under reduced pressure on a rotary evaporator.
General procedure B: Cleavage of the N-tboc protecting group from N-tboc protected cytisine derivatives
The concentrated aqueous solution of the N-tboc protected cytisine derivative (approx. 70 mL) was put into a 80 mL microwave glass tube, sealed and placed into the microwave cavity. Microwave irradiation of 150 W was used and the temperature ramped from rt to 150 °C. Once 150 °C was reached the reaction mixture was held for 30 min. before the mixture was allowed to cool to rt. The reaction vessel was opened and the solvent was evaporated by lyophilization for at least 24 h. Seeds and pods of Laburnum anagyroides watereri were collected in the Cologne-Bonn area (Germany) in the months September and October. The plant material was air-dried at least for 3 months and ground to a powder consistence. The plant material was extracted with CH 2 Cl 2 /MeOH/aq. NH 3 (10:4:1) through homogenization by Ultra-turrax for 8 hours. The evaporated solvents were replaced, exactly the same amounts of each solvent were added to the homogenate during the extraction. The homogenate was centrifuged (2,000 x min, 40 min) and the supernatant collected. The dark green solution was concentrated under reduced pressure to the final volume of 500 ml and extracted with 1M HCl (3 x 100 ml). The aqueous acid solution was rendered alkaline with 26% NH 4 OH (pH [11] [12] and the free base extracted with CH 2 Cl 2 (10 x 100 ml). The organic layers were collected and the solvent evaporated in vacuo. The dark green/brownish residue was purified by column chromatography on silica gel column with CHCl 3 /MeOH (6:1). The alkaloid 1 was recrystallized from perchloroethylene or directly used in the next step (synthesis of N-tboccytisine 2). Isolated yields ranged from 0.11 to 0. 25.6, 27.0, 34.9, 49.1, 52.3, 53.3, 104.2, 115.7, 138.1, 150.7, 162.8 27.5, 28.0, 34.8, 48.9, 50.5, 51.6, 80.3, 105.8, 117.1, 138.9, 148.7, 154.5, 163.4 . LC/ESI-MS: positive mode m/z = 291.3 ([M + H] + ). Purity (> 99.9 %). IR (KBr, cm −1 ) 3217, 3099, 1687 3217, 3099, , 1654 3217, 3099, , 1465 3217, 3099, , 1445 3217, 3099, , 1421 3217, 3099, , 1364 N-tboc-cytisine 2 (1 g, 3.44 mmol) and N-bromosuccinimide (613 mg, 3.44 mmol, 1 eq) were stirred in 30 ml CH 2 Cl 2 at 60°C for 2 hours. The reaction mixture was allowed to cool to rt and the solvent was evaporated in vacuo. The oily residue was dissolved in 150 ml MeOH/H 2 O (60:40) and the two isomers were separated and purified by preparative HPLC. Product 3 was obtained in 38-52 % yield as a white crystalline powder; mp 131 °C. 1 H NMR (500 MHz, CDCl 3 ) δ 1.30 (s, 9H), 1.94 (t, J = 13.2 Hz, 2H), 2.40 (br s, 1H), 2.99-3.06 (m, 3H), 3.85 (dd, J = 15.5, 6.3 Hz, 1H), 2H), 4.23 (d, J = 15.8 Hz, 1H), 5.96 (br s, 1H), 7.64 (dd, J = 7.6 Hz, 1H) . 13 C NMR (125 MHz, CDCl 3 ) δ 26.0, 27.4, 28.0, 34.7, 49.2, 50.2, 51.4, 80.6, 105.7, 112.5, 140.8, 148.5, 154.4, 159.4 . LC/ESI-MS: positive mode m/z = 369.0 and 371.0 ([M + H] + ). Purity (> 99.9 %). IR (KBr, cm −1 ) 3092, 2974, 1692, 1648, 1587, 1423, 1365, 1237, 1129, 760 26.3, 27.9, 35.7,50.2, 53.0, 54.0, 105.0, 127.2, 127.4, 128.0, 128.6, 137.0, 137.4, 150.3, 162 2, 27.8, 35.7, 50.3, 53.0, 53.9, 105.0, 122.8, 123.9, 133.2, 136.1, 137.2, 148.2, 149.1, 151.5, 161.9 . HRMS (EI) calcd for C 16 H 17 N 3 O 267.1371, found 267.1376.
9-pyridin-4-yl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one) [3-(Pyridin-4′-yl)cytisine] (6)
The Suzuki reaction was performed according to general procedure A with 3-bromo-N-tboccytisine 3 (100 mg, 0.27 mmol), 4-pyridineboronic acid (49 mg, 0.41 mmol), K 3 PO 4 (126 mg, 0.6 mmol), Pd(PPh 3 ) 4 (30 mg, 0.027 mmol), DME and H 2 O. The reaction time was 90 min. For the SPE purification a mixture of MeOH/H 2 O 60:40 v/v (100 mL) was used. After the HPLC purification, general procedure B was used for the N-tboc deprotection. Final product 6 was obtained as a yellow solid (45 mg, 62 %). mp n.d. °C. 1 H NMR (500 MHz, CDCl 3 ) δ 1.96 (br s, 2H), 2.36 (br s, 1H), 2.94 (br s, 1H), 3.00 (ddd, J = 12.3, 2.5, 1.2 Hz, 1H), 3.04 (d, J = 12.3 Hz, 1H), 3.07 (dd, J = 12.3, 2.5 Hz, 1H), 3.11 (dd, J = 12.3, 2.5 Hz, 1H), 3.95 (dd, J = 15.8, 6.6 Hz, 1H), 4.16 (d, J = 15.8 Hz, 1H), 6.13 (d, J = 7.4 Hz, 1H), 7.57 (d, J = 7.4 Hz, 1H), 7.67 (dd, J = 6.1, 1.6 Hz, 2H), 8.57 (dd, J = 6.1, 1.6 Hz, 2H). 13 C NMR (125 MHz, CDCl 3 ) δ 26. 2, 27.8, 35.8, 50.3, 53.0, 53.9, 104.9, 122.8, 123.9, 137.8, 144.9, 149.6, 152.6, 161.5 . HRMS (EI) calcd for C 16 4, 27.9, 35.7, 50.2, 53.0, 54.0, 100.9, 104.9, 108.0, 109.4, 122.1, 127.1, 131.4, 136.4, 146.8, 147.3, 149.9, 162 
General procedure C: Synthesis of N-tboc protected bispidinecarboxamides
Methyl iodide (570 mg, 4 mmol) was added to a stirred solution of 12 (320 mg, 1 mmol) dissolved in dry MeCN (2 mL) and dry THF (2 mL) at rt. The volatiles were removed under reduced pressure after 24 h, the residue was dissolved in dry MeCN (4 mL), and Et 3 N (101 mg, 1 mmol) and the appropriate carboxylic acid (1 mmol) were added. The solution was allowed to stir at rt for 12-120 h before the volatiles were removed under reduced pressure. The residue was purified by flash chromatography (silica gel, mixtures of CH 2 Cl 2 and MeOH -40:1, 20:1 or 9:1).
General procedure D: Synthesis of N-tboc protected bispidinecarboxamides
The appropriate carboxyl chloride (1 mmol), either neat or dissolved in dry toluene (1-2 mL), was added dropwise to a stirred solution of N-tboc-bispidine 11 (230 mg, 1 mmol) and Et 3 N (101 mg, 1 mmol) in dry toluene (5 mL) at rt. The volatiles were removed under reduced pressure after 2 h and the residue was purified by flash chromatography (silica gel, mixtures of CH 2 Cl 2 and MeOH -40:1, 20:1 or 9:1).
General procedure E: Synthesis of N-tboc protected bispidinecarboxamides
The appropriate carboxylic acid (1 mmol) and N-tboc-bispidine 11 (248 mg, 1.1 mmol) were dissolved in dry CH 2 Cl 2 (5 mL) and cooled to 0 °C. DMAP (6.1 mg, 0.05 mmol) and DCC (206 mg, 1 mmol) were added and the mixture was allowed to warm up and stir at rt. The precipitate was filtered off after 12 h and washed with cold CH 2 Cl 2 (2 mL) The solvent of the filtrate was evaporated under reduced pressure and the residue was purified by flash chromatography (silica gel, mixtures of CH 2 Cl 2 and MeOH -40:1. 20:1 or 9:1).
General procedure F: Cleavage of the N-tboc protecting group from N-tboc protected bispidine derivatives
HCl in 1,4-dioxane (4 M, 4-5 mL) was added to a stirred solution of the N-tboc protected bispidine derivative (0.2 -1.0 mmol), dissolved in 4-5 mL of 1,4-dioxane, and the mixture was allowed to stir at rt for 2-12 h. The volatiles were removed under reduced pressure and before the residue was dissolved in KOH solution (0.25 M, 20 mL) and extracted with of CH 2 Cl 2 (3-5 x 20 mL). The combined organic layers were washed with saturated NaHCO 3 solution (10 mL), water (10 mL), dried with MgSO 4 and filtered. The product was obtained after evaporating the solvent under reduced pressure.
General procedure G: Cleavage of the N-tboc protecting group from N-tboc protected bispidine derivatives
The N-tboc protected bispidine derivative (0.2 -1.0 mmol) was dissolved in dry CH 2 Cl 2 (5 mL), anhydrous ZnBr 2 (2-3 equiv.) was added, and the mixture was allowed to stir at rt for 12-120 h. After the removal of the volatiles under reduced pressure the residue was dissolved in KOH solution (0.25 M, 20 mL) and extracted with CH 2 Cl 2 (5 x 20 mL). The combined organic layers were washed with saturated NaHCO 3 solution (10 mL), water (10 mL), dried over MgSO 4 , and filtered. The product was obtained after evaporating the solvent under reduced pressure.
General procedure H. Formation of fumaric acid salts of bispidine derivatives
The amine (0.2 -1.0 mmol) was dissolved in a mixture of Et 2 O and MeOH (9:1, 2-5 mL). A saturated solution of fumaric acid in the same mixture of solvents was added dropwise to a stirred solution of the amine until no further precipitation was observed. The solution was kept at 4-8 °C overnight before the precipitate was filtered off and washed with the same mixture of solvents (2 x 5 mL) and dry Et 2 O (5 mL). The solid was dissolved in water (20-30 mL) , and freeze-dried.
General procedure I. Formation of fumaric acid salts of bispidine derivatives
The amine (0.2 -1.0 mmol) was dissolved in isopropanol (3-5 mL) , filtered, and heated to 70-80 °C. The same molar amount of fumaric acid was dissolved in isopropanol (3 mL) and also heated to 70-80 °C. The two solutions were combinedf and allowed to cool to rt. Dry Et 2 O (10 mL) were added and the mixture was kept at 4-8 °C overnight. The solid was filtered off, washed with dry Et 2 O (3 x 5 mL), dissolved in water (20-30 mL) , and freezedried.
(1R,5S)-tert-butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (9)
Compound 9 was obtained following the synthetic procedures published by Stead et al.{{2 Stead,D. 2005 ;}} A solution of tert-butyl 4-oxopiperidine-1-carboxylate 8 (10.0 g, 50.2 mmol), acetic acid (2.9 mL, 50.9 mmol), and benzylamine (5.5 mL, 50.4 mmol) in methanol (40 mL) was added dropwise to a stirred suspension of paraformaldehyde (3.32 g, 110.6 mmol) . The resulting mixture was heated under reflux for 1 h before another portion of paraformaldehyde (3.32 g, 110.6 mmol) was added. This mixture was heated at reflux for additional 5 h before the reaction was allowed to cool to rt and the solvent was evaporated 7, 47.7, 50.0, 50.6, 58.8, 59.1, 62.0, 80.2, 127.4, 128.5, 128.9, 137.5, 154.9, 213.6 
(1R,5S)-tert-butyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (10)
A solution of 9 (18.9 g, 57.2 mmol), NaOH (10.0 g, 250 mmol), and hydrazine hydrate (80 %, 10.0 mL, 160 mmol) in 150 mL of diethylene glycol was heated at 125 °C under reflux conditions. After 2 h the reflux condenser was exchanged for a Dean-Stark apparatus and the mixture was heated at 140 °C for additional 8 h. After cooling to rt 250 mL of water were added and the resulting mixture was extracted with toluene (4 x 150 mL). The combined organic layers were washed with saturated solution (1 x 30 mL), water (2 x 
(1R,5S)-tert-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate fumaric acid salt (11F)
200 mg of Pd/C (5 %) was added to a solution of 10 (1.5 g, 4.74 mmol) in MeOH (7 mL) and the mixture was allowed to react under an atmosphere of hydrogen (10 psi 2, 30.3, 30.5, 50.7, 50.9, 85.3, 137.6, 161.0, 174.4 
(1R,5S)-tert-butyl 7-(1H-imidazole-1-carbonyl)-3,7-diazabicyclo[3.3.1]nonan-3-carboxylate (12)
N-tBoc-bispidine 11 (1.5 g, 6.63 mmol) was dissolved in dry THF (20 mL) 8, 28.5, 31.2, 47.4, 48.8, 50.2, 51.8, 80.3, 118.0, 129.4, 137.0, 151.8, 155 . 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(3-methylisoxazol-5-yl)ethanone fumaric acid salt (13F)
The N-tboc protected compound was obtained by using the general procedure C with 3-methyl- 3, 28.0, 28.4, 30.1, 35.3, 49.1, 50.2, 50.5, 52.4, 108.1, 137.6, 164.7, 168.7, 174.4, 174.5 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(3,4,5-trimethoxyphenyl)propan-1-one fumaric acid salt (14F)
The N-tboc protected compound was obtained by using the general procedure C with 3- (3,4,5-trimethoxyphenyl) 4, 30.2, 34.1, 37.9, 48.8, 50.1, 50.5, 52.2, 58.9, 63.8, 108.9, 137.5, 138.1, 140.7, 155.3, 174.4, 180. 17.6, 27.3, 28.1, 28.4, 28.6, 30.3, 49.5, 50.3, 50.6, 52.3, 128.9, 129.6, 131.7, 137.6, 143.3, 174.5 The N-tboc protected compound was obtained by using the general procedure C with trans-3-phenylacrylic acid (148 mg, 1 mmol) for 48 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (256 mg, 72 %) was obtained. The N-tboc protection group of this solid (240 mg, 0.67 mmol) was cleaved using the general procedure G with anhydrous 2, 28.5, 30.3, 49.4, 50.3, 50.6, 52.4, 120.5, 130.9, 132.0, 133.3, 137.5, 137.6, 146.5, 173.9, 174.5 1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(2-methoxyphenyl) prop-2-en-1-one fumaric acid salt (17F)
(E)-
The N-tboc protected compound was obtained by using the general procedure C with trans -3-(2-methoxyphenyl) 2, 28.5, 30.3, 49.4, 50.3, 50.6, 52.4, 58.7, 115.0, 120.9, 124.1, 126.2, 131.5, 134.8, 137.5, 141.5, 160.6, 174 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(3-chlorophenyl)prop-2-en-1-one fumaric acid salt (18F)
The N-tboc protected compound was obtained by using the general procedure C with trans -3-(3-chlorophenyl) 2, 28.5, 30.3, 49.4, 50.2, 50.5, 52.4, 121.7, 129.3, 130.4, 132.8, 133.3, 137.1, 137.6, 139.4, 144.9, 173.4, 174.4 The N-tboc protected compound was obtained by using the general procedure C with trans -3-(3-bromophenyl) 2, 28.5, 30.3, 49.4, 50.2, 50.5, 52.4, 121.7, 125.2, 129.7, 133.3, 133.5, 135.7, 137.5, 139.6, 144.8, 173.4, 174.5 The N-tboc protected compound was obtained by using the general procedure C with trans -3-(3-nitrophenyl) 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(4-methoxyphenyl)prop-2-en-1-one fumaric acid salt (21F)
The N-tboc protected compound was obtained by using the general procedure C with trans- 3-(4-methoxyphenyl) 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(furan-2-yl)prop-2-en-1-one fumaric acid salt (22F)
The N-tboc protected compound was obtained by using the general procedure C with 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(thiophen-2-yl)prop-2-en-1-one fumaric acid salt (23F)
The N-tboc protected compound was obtained by using the general procedure C with trans -3-(thiophen-2-yl) 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(thiophen-3-yl)prop-2-en-1-one fumaric acid salt (24F)
The N-tboc protected compound was obtained by using the general procedure C with trans- 3-(thiophen-3-yl) 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(pyridin-4-yl)prop-2-en-1-one fumaric acid salt (25F)
The N-tboc protected compound was obtained by using the general procedure C with trans- 3-(pyridin-4-yl) 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(benzo[d][1,3]dioxol-5-yl)prop-2-en-1-one fumaric acid salt (26F)
The N-tboc protected compound was obtained by using the general procedure C with trans -3-(benzo[d] 28.5, 30.3, 49.4, 50.3, 50.6, 52.3, 104.6, 109.3, 111.6, 118.0, 127.6, 131.9, 137.5, 146.5, 150.8, 152.0, 173.9, 174.3 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(naphthalen-1-yl)prop-2-en-1-one fumaric acid salt (27F)
The N-tboc protected compound was obtained by using the general procedure C with trans -3-(naphthalene-1-yl) 4, 30.2, 49.3, 50.2, 50.5, 52.2, 122.8, 126.0, 127.9, 128.6, 129.3, 130.0, 131.6, 133.3, 133.8, 134.5, 136.2, 137.5, 143.0, 173.4, 174.3 
(1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl(biphenyl-4-yl)methanone fumaric acid salt (28F)
The N-tboc protected compound was obtained by using the general procedure C with 4-biphenylcarboxylic acid (198 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a clear oil (293 mg, 72 %) was obtained. The N-tboc protection group of this oil (250 mg, 0.61 mmol) was cleaved using the general procedure F for 12 h and a clear oil 28 (141 mg, 75 %) was obtained after extraction. This oil 28 (60 mg, 0.20 mmol) was transferred to its fumaric acid salt 28F by using the general procedure I with fumaric acid (23 mg, 0.20 mmol 5, 30.3, 49.4, 49.6, 50.6, 54.8, 129.9, 130.0, 130.5, 131.2, 132.1, 136.2, 137.6, 142.4, 145.5, 174.6, 177.8 
(1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl(phenyl)methanone fumaric acid salt (29F)
The N-tboc protected compound was obtained by using the general procedure D with benzoyl chloride (141 mg, 1 mmol 3, 29.1, 48.3, 48.5, 128.3, 129.7, 131.2, 136.2, 136.8, 171.3, 175.4 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-phenylethanone fumaric acid salt (30F)
The N-tboc protected compound was obtained by using the general procedure D with phenylacetyl chloride (155 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (343 mg, 98 %) was obtained. The N-tboc protection group of this solid (310 mg, 0.90 mmol) was cleaved using the general procedure F for 12 h and an off white solid 30 (210 mg, 97 %) was obtained after extraction. This solid 30 (180 mg, 0.74 mmol) was transferred to its fumaric acid salt 30F by using the general procedure H. Compound 30F (158 mg, 66 %) was obtained as a white solid in 62 % yield over three steps; mp 145-147 °C (dec 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(pyridine-3-yl)ethanone fumaric acid salt (31F)
The N-tboc protected compound was obtained by using the general procedure E with 2-(pyridine-3-yl)acetic acid (137 mg 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-phenylpropan-1-one fumaric acid salt (32F)
The N-tboc protected compound was obtained by using the general procedure D with 3-phenylpropionic acid chloride (169 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (355 mg, 97 %) was obtained. The N-tboc protection group of this solid (340 mg, 0.95 mmol) was cleaved using the general procedure F for 12 h and a clear oil 32 (235 mg, 96 %) was obtained after extraction. This oil 32 (103 mg, 0.40 mmol) was transferred to its fumaric acid salt 32F by using the general procedure I with fumaric acid (46 mg, 0.40 mmol 0, 28.3, 30.1, 33.6, 37.9, 48.8, 50.2, 50.6, 52.2, 129.4, 131.4, 131.7, 137.5, 143.7, 174.4, 180 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(2-chlorophenoxy)ethanone fumaric acid salt (33F)
The N-tboc protected compound was obtained by using the general procedure C with (2-chlorophenoxy)acetic acid (187 mg, 1 mmol) for 24 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (186 mg, 47 %) was obtained. The N-tboc protection group of this oil (130 mg, 0.33 mmol) was cleaved using the general procedure F for 12 h and a white solid 33 (95 mg, 98 %) was obtained after extraction. This solid 33 (46 mg, 0.16 mmol) was transferred to its fumaric acid salt 33F by using the general procedure I with fumaric acid (18 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(2,3,4,5,6-pentafluorophenyl)ethanone fumaric acid salt (34F)
The N-tboc protected compound was obtained by using the general procedure E with 2,3,4,5,6-pentafluorophenylacetic acid (226 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (370 mg, 85 %) was obtained. The N-tboc protection group of this solid (200 mg, 0.46 mmol) was cleaved using the general procedure F for 4 h and a white solid 34 (149 mg, 97 %) was obtained after extraction. This solid 34 (145 mg, 0.43 mmol) was transferred to its fumaric acid salt 34F by using the general procedure I with fumaric acid (50 mg, 0.43 mmol). Compound 34F (149 mg, 79 %) was obtained as a white solid in 65 % yield over three steps; mp 176-180 °C (dec. 5, 27.0, 28.6, 29.5, 47.9, 48.8, 49.1, 50.7, 136.4, 172.5, 173.7 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(4-(methylsulfonyl)phenyl)ethanone fumaric acid salt (35F)
The N-tboc protected compound was obtained by using the general procedure E with 4-(methylsulfonyl)phenylacetic acid (214 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a white solid (296 mg, 70 %) was obtained. The N-tboc protection group of this solid (246 mg, 0.58 mmol) was cleaved using the general procedure F for 2 h and a white solid 35 (147 mg, 78 %) was obtained after extraction. This solid 35 (147 mg, 0.46 mmol) was transferred to its fumaric acid salt 35F by using the general procedure I with fumaric acid (53 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(pyridine-4-yl)ethanone fumaric acid salt (36F)
The N-tboc protected compound was obtained by using the general procedure E with 2-(pyridine-4-yl)acetic acid (137 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (276 mg, 80 %) was obtained. The N-tboc protection group of this solid (220 mg, 0.64 mmol) was cleaved using the general procedure F for 2 h and a clear oil 36 (128 mg, 82 %) was obtained after extraction. This oil 36 (128 mg, 0.52 mmol) was transferred to its fumaric acid salt 36F by using the general procedure I with fumaric acid (61 mg, 0.52 mmol). Compound 36F (157 mg, 74 %) was obtained as a white solid in 48 % yield over three steps; mp 174-175 °C (dec) 8, 26.2, 27.8, 40.8, 46.9, 48.0, 48.2, 49.9, 129.5, 135.6, 141.5, 157.0, 173.08, 173.14 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(benzo[d][1,3]dioxol-5-yl)ethanone fumaric acid salt (37F)
The N-tboc protected compound was obtained by using the general procedure E with 2- 8, 26.3, 27.9, 40.8, 46.9, 48.0, 48.4, 50.2, 101.8, 109.3, 110.4, 123.2, 128.7, 135.5, 146.8, 148.1, 172.2, 176.6 2869 , 1698 , 1659 , 1596 , 1443 , 1398 , 1253 , 1213 , 1192 , 1034 6.48 (s, 1.36H), 7.29 (d, J = 7.8 Hz, 1H), 7.42 (m, 2H), 7.61 (s, 1H), 3H) . 13 C NMR (100 MHz, DMSO-d 6 ) δ 25.4, 25.7, 28.1, 40.6, 45.9, 46.7, 46.8, 49.0, 125.4, 125.9, 127.33, 127.34, 127.4, 127.5, 128.3, 131.7, 133.0, 133.6, 135.1, 167.9, 171.6 
1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-2-(pyridine-4-yl)propanone fumaric acid salt (39F)
The N-tboc protected compound was obtained by using the general procedure E with 3-(pyridine-3-yl)propionic acid (151 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (232 mg, 64 %) was obtained. The N-tboc protection group of this solid (190 mg, 0.53 mmol) was cleaved using the general procedure F for 2 h and a clear oil 39 (120 mg, 88 %) was obtained after extraction. This oil 39 (120 mg, 0.46 mmol) was transferred to its fumaric acid salt 39F by using the general procedure I with fumaric acid (54 mg, 0.46 mmol 8, 26.1, 27.7, 34.2, 46.6, 48.0, 48.3, 49.6, 127.5, 135.6, 139.7, 141.7, 142.3, 147.5, 173.1, 176.3 The N-tboc protected compound was obtained by using the general procedure E with trans-3- (4- .6, 28.4, 46.7, 115.7 (d . HRMS (EI) calcd for C 16 H 19 FN 2 O 275.1554 , found 275.1547 . IR (cm -1 ) 2952 , 2851 , 2717 , 2640 , 1732 , 1652 , 1620 , 1558 , 1507 , 1316 , 1217 
(E)-1-((1R,5S)-3,7-diazabicyclo[3.3.1]nonan-3-yl)-3-(pyridin-3-yl)prop-2-en-1-one fumaric acid salt (41F)
The N-tboc protected compound was obtained by using the general procedure E with trans -3-(pyridine-3-yl) 26.3, 28.0, 47.2, 48.0, 48.3, 50.2, 123.4, 126.7, 133.8, 135.7, 137.9, 141.0, 144.9, 145.7, 170.5, 173.5 5, 26.0, 28.6, 45.6, 47.3, 47.4, 50.3, 82.5, 89.4, 120.0, 128.9, 130.4, 132.2, 135.0, 154.3, 167.7 8, 26.0, 28.2, 46.4, 47.4, 47.5, 51.1, 56.8, 86.7, 89.1, 109.3, 112.5, 121.9, 133.7, 134.9, 136.0, 156.7, 161.8, 169.7 6, 26.1, 28.1, 46.5, 47.7, 48.1, 51.5, 56.1, 80.7, 94.2, 118.0, 118.1, 120.9, 126.2, 130.8, 135.3, 157.9, 159.4, 172 .5, 25.9, 28.5, 45.6, 47.1, 47.3, 50.3, 55.4, 81.7, 90.1, 111.7, 114.6, 134.1, 135.0, 154.6, 160.8, 167.7 .5, 25.9, 28.5, 45.6, 47.0, 47.2, 50.3, 55.6, 55.7, 81.4, 90.4, 111.6, 111.9, 114.9, 126.2, 135.0, 148.6, 150.9, 154.6, 167.8 The N-tboc protected compound was obtained by using the general procedure E with 3-(3-chloro-4-methoxyphenyl)propiolic acid (211 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents an off-white solid (412 mg, 98 %) was obtained. The N-tboc protection group of this solid (360 mg, 0.86 mmol) was cleaved using the general procedure F for 4 h and an off-white solid 47 (270 mg, 99 %) was obtained after extraction. This solid 47 (270 mg, 0.85 mmol) was transferred to its fumaric acid salt 47F by using the general procedure I with fumaric acid (98 mg, 0.85 mmol). Compound 47F (270 mg, 74 %) was obtained as an offwhite solid in 72 % yield over three steps; mp 169-174 °C (dec 6, 26.3, 28.5, 46.8, 47.8, 48.1, 51.6, 57.3, 82.4, 92.3, 113.5, 114.3, 122.8, 134.7, 134.9, 136.3, 157.7, 157.7, 170.9 Responses of oocytes expressing diverse nAChR subtypes to 1 or 10 μM of selected compounds (numbering are following the sequence in the tables) relative to ACh control responses. Responses of oocytes expressing diverse nAChRs to compounds co-applied at 1 μM with ACh compared to responses to ACh alone. Bars above zero indicate additive effects; bars below zero indicate reduced responses. 
